Bioasis Provides Corporate Update and Announces Suspension of Operations

NEW HAVEN, Conn., June 20, 2023 -- BIOASIS TECHNOLOGIES INC. , a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor... | June 20, 2023

Related Keywords

United Kingdom ,Switzerland ,Swiss ,British ,Chiesi Farmaceutici ,Deborah Rathjen ,Midatech Pharma ,Company Or Bioasis ,British Columbia Securities Commission ,Venture Exchange ,Biodexa Pharmaceuticals ,Lind Global Macro Fund ,Board Of Directors Bioasis Technologies Inc ,Regulation Services Provider ,Shadow Lake Group ,Given The Company ,Maxim Group ,Swiss Biotech Advisors ,Bioasis Technologies ,Executive Chair ,